Deals
Teva Makes Concessions in EU Review of Bid for Allergan Unit
- EU extends deadline to rule on the deal until March 10
- Concessions may allow companies win early approval for deal
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. made concessions to European Union regulators for its takeover of Allergan Plc’s generics unit, potentially averting a lengthy probe into the $40.5 billion tie-up.
The EU extended its deadline to rule on the deal until March 10 after the companies submitted commitments, according to a website filing on Friday, giving no details on what the companies had offered. Businesses can allay regulators’ antitrust concerns by pledging to sell units or change their future behavior.